First Time Loading...

Mereo Biopharma Group PLC
NASDAQ:MREO

Watchlist Manager
Mereo Biopharma Group PLC Logo
Mereo Biopharma Group PLC
NASDAQ:MREO
Watchlist
Price: 2.74 USD -2.49% Market Closed
Updated: Apr 27, 2024

Mereo Biopharma Group PLC
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mereo Biopharma Group PLC
Operating Income Peer Comparison

Comparables:
CNTA
AUTL
BCYC
IMCR
GNS

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Mereo Biopharma Group PLC
NASDAQ:MREO
Operating Income
-£43.6m
CAGR 3-Years
-3%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Operating Income
-$171.3m
CAGR 3-Years
-154%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Operating Income
-$175.5m
CAGR 3-Years
-1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Operating Income
-$189.4m
CAGR 3-Years
-53%
CAGR 5-Years
-54%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Operating Income
-£59.6m
CAGR 3-Years
13%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Operating Income
£53m
CAGR 3-Years
8%
CAGR 5-Years
4%
CAGR 10-Years
4%

See Also

What is Mereo Biopharma Group PLC's Operating Income?
Operating Income
-43.6m GBP

Based on the financial report for Dec 31, 2022, Mereo Biopharma Group PLC's Operating Income amounts to -43.6m GBP.

What is Mereo Biopharma Group PLC's Operating Income growth rate?
Operating Income CAGR 3Y
-3%

Over the last year, the Operating Income growth was -108%. The average annual Operating Income growth rates for Mereo Biopharma Group PLC have been -3% over the past three years .